89bio, Inc. (ETNB)
NASDAQ: ETNB · IEX Real-Time Price · USD
7.60
-0.16 (-2.06%)
At close: Jul 2, 2024, 4:00 PM
7.98
+0.38 (5.00%)
After-hours: Jul 2, 2024, 7:53 PM EDT
Company Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.
The company was incorporated in 2018 and is headquartered in San Francisco, California.
89bio, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Nov 11, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 70 |
| CEO | Rohan Palekar |
Contact Details
Address: 142 Sansome Street, Second Floor San Francisco, California 94104 United States | |
| Phone | (415) 432-9270 |
| Website | 89bio.com |
Stock Details
| Ticker Symbol | ETNB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001785173 |
| CUSIP Number | 282559103 |
| ISIN Number | US2825591033 |
| Employer ID | 83-1114349 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rohan Palekar | Chief Executive Officer and Director |
| Quoc Le-Nguyen | Chief Technical Operations Officer and Head of Quality |
| Dr. Harry Mansbach M.D. | Chief Medical Officer |
| Ryan Stephen Martins | Chief Financial Officer |
| Shiva K. Natarajan CPA | Senior Vice President of Finance and Principal Accounting Officer |
| Annie J. Chang M.B.A. | Vice President of Investor Relations and Corporate Communications |
| Amanda Kurihara | Vice President of People and Culture |
| Yun Bai Ph.D. | Vice President and Head of Chemistry, Manufacturing and Controls ( CMC ) |
| Melissa Abel | Senior Vice President of Commercial Strategy |
| Paul Shin | Senior Vice President of Research & Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 31, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 19, 2024 | ARS | Filing |
| Apr 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2024 | 8-K | Current Report |
| Apr 10, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 144 | Filing |
| Mar 8, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |